Abstract YO30
Case summary
A 53-year-old man presented with an 11-month history of a painless neck mass. On examination, he had a 10 x 5 cm mass at the left carotid triangle, and a fungating mass at the left tonsillar fossa, which on CT scan was 3.2 x 2.2 cm and invading into the parapharyngeal space.
Biopsy revealed an undifferentiated malignancy. Immunohistochemistry was negative for CK, LCA, EMA, synaptophysin, chromogranin and 34beta-E12, positive for vimentin and focally positive for S-100, favoring malignant melanoma. However, both HMB-45 and melan-A were negative, leading to a classification of undifferentiated sarcoma.
Chest and abdominal CT scan were negative for distant metastases. The tumor was deemed unresectable due to its close attachment to the great vessels, hence a sequential chemoradiation approach was pursued. He underwent six cycles of doxorubicin (60 mg/m2), resulting in 80% tumor regression. Unfortunately, he was lost to follow-up and was unable to undergo radiotherapy. He returned eight months later with re-enlargement of the neck mass to 6 x 5 cm. He remained free of distant metastases, and underwent two cycles of dacarbazine (250 mg/m2, day 1-5), which did not confer any response.
The indolent behavior of the tumor prompted pathological re-evaluation. Further staining showed diffuse positivity for CD21 and negative for CD1A and CD34, consistent with follicular dendritic cell sarcoma. The patient underwent three cycles of gemcitabine (1000 mg/m2, day 1 and 8) plus docetaxel (75 mg/m2, day 1), resulting in 50% tumor regression. This allowed dissection of level IB – V lymph nodes, which found disease in 10/23 nodes. He subsequently underwent adjuvant radiotherapy for the neck and primary radiotherapy for the tonsillar mass, with weekly gemcitabine (400 mg/m2) as a radiosensitizer. Evaluation three months post-treatment did not show any sign of disease progression.
Follicular dendritic cell sarcoma is very rare, accounting for <0.4% of soft tissue sarcomas. Only 60 cases of tonsillar occurrence have been reported in literature. Tonsillectomy is sufficient in most cases. For our patient, a trimodality approach done due to the presence of high risk features (R2 resection, LN involvement, tumor recurrence) provided good disease control.
Clinical trial identification
Editorial acknowledgement
Resources from the same session
273P - MALT1- A20 and NF-κB expression pattern in patients with non-Hodgkin lymphomas
Presenter: Alshimaa Alhanafy
Session: Poster display session
Resources:
Abstract
274P - Treatment stratification of non-Hodgkin large B-cell lymphoma patients based on the identification of mutational c-MYC gene
Presenter: Raimkul Karakulov
Session: Poster display session
Resources:
Abstract
275P - Primary central nervous system lymphoma treated with high-dose methotrexate and rituximab: Preliminary results in Vietnam
Presenter: Gia Nguyen Hoang
Session: Poster display session
Resources:
Abstract
276P - Chronic myelod leukemia in chronic phase (CML-CP) with lymphadenopathy at diagnosis: A retrospective analysis
Presenter: GEDALA Veni Prasanna
Session: Poster display session
Resources:
Abstract
277P - Characteristics of BCR-ABL rearrangement variants in Pakistani patients with chronic myeloid leukemia and acute lymphocytic leukemia
Presenter: Zeeshan Ahmed
Session: Poster display session
Resources:
Abstract
278P - A systematic literature review of the cost-effectiveness of treatments, costs, and resource use in patients with Burkitt lymphoma
Presenter: Gautamjeet Mangat
Session: Poster display session
Resources:
Abstract
280P - Risk stratification of CML-CP in a real-world scenario, comparison of S.H.E. with rate of fall of BCR/ABL
Presenter: Kundan Mishra
Session: Poster display session
Resources:
Abstract
281P - Selective depletion of tumour-associated SAMHD1 by HSP90 inhibitors enhances the anti-AML effect of cytarabine
Presenter: Jing Sun
Session: Poster display session
Resources:
Abstract
282P - Inhibition of miR-144 and miR-199 promote myeloma pathogenesis via upregulation of versican and FAK/STAT3 signaling
Presenter: Nidh Gupta
Session: Poster display session
Resources:
Abstract
283P - Effect of study-level factors on treatment-free remission rate in patients with chronic myeloid leukemia: A systematic review and meta-analysis
Presenter: Jinhyun Cho
Session: Poster display session
Resources:
Abstract